Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01780662 (Clinical Trial/ Brentuximab vedotin/ SGN-30)

Study Title
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT01780662)

Trial description
This phase I/II trial studies the side effects and the best dose of brentuximab vedotin (also known SGN-035) as  when given together with gemcitabine hydrochloride and to see how well they work in treating younger patients with Hodgkin lymphoma that has returned or does not respond to treatment.

Monoclonal antibody-drug conjugates such as brentuximab vedotin, may find cancer cells and help kill them. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

It is expected that giving brentuximab vedotin together with gemcitabine hydrochloride may kill more cancer cells.

This trial is sponsored by the National Cancer Institute (NCI).

Study data

  • Condition: Hodgkin Lymphoma
  • Interventions:
  • Drugs used in this trial
  • Phase: I & II
  • Estimated Enrollment: 72
  • Start: January 2013
  • Estimated Primary Completion: October 2015 (Final data collection date for primary outcome measure)
  • Last verified: March 2015

Study Schematic

Screen Shot 2016-07-11 at 10.38.21 AM


Last Editorial review: July 11, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.

Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar